Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 14Thoracic 2Gastrointestinal 2Breast 2Sarcoma 1Plasma cell 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Glioblastoma 9Gliosarcoma 6Brain Neoplasms 6Rectal Neoplasms 2Oligodendroglioma 2Neoplasms 2Melanoma 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Neoplasms 2Astrocytoma 2Spinal Cord Neoplasms 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Optic Nerve Glioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1

Interventions

Filgrastim 12Carboplatin 10Paclitaxel 9Peripheral Blood Stem Cell Transplantation 7Cyclophosphamide 7Ifosfamide 6Temozolomide 5Cisplatin 5pembrolizumab 4Nivolumab 4Gemcitabine 4Etoposide 4Docetaxel 4fludarabine 3Thiotepa 3Specimen Handling 3Psychiatric Rehabilitation 3Melphalan 3Magnetic Resonance Spectroscopy 3Immunologic Techniques 3Fluorodeoxyglucose F18 3Flow Cytometry 3Bevacizumab 3Amifostine 3ulixertinib 2trametinib 2sargramostim 2sapanisertib 2pegfilgrastim 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × cediranib × CNS × Clear all
NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡